Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1936 1
1946 1
1953 1
1954 1
1955 1
1959 4
1961 1
1963 2
1964 4
1965 8
1966 1
1967 2
1968 1
1969 3
1970 3
1971 2
1972 3
1973 3
1974 3
1975 4
1976 5
1977 6
1978 17
1979 11
1980 14
1981 12
1982 10
1983 18
1984 27
1985 35
1986 24
1987 36
1988 36
1989 43
1990 31
1991 35
1992 36
1993 24
1994 21
1995 29
1996 21
1997 24
1998 16
1999 22
2000 16
2001 19
2002 21
2003 18
2004 17
2005 14
2006 15
2007 14
2008 18
2009 11
2010 12
2011 10
2012 12
2013 20
2014 18
2015 17
2016 19
2017 22
2018 11
2019 23
2020 14
2021 21
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

941 results
Results by year
Filters applied: . Clear all
Page 1
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P. Widmark A, et al. Among authors: norman d. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18. Lancet. 2019. PMID: 31227373 Clinical Trial.
Preface.
Yoshikawa TT, Norman DC. Yoshikawa TT, et al. Among authors: norman dc. Clin Geriatr Med. 2016 Aug;32(3):xiii-xiv. doi: 10.1016/j.cger.2016.06.001. Clin Geriatr Med. 2016. PMID: 27394027 No abstract available.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A. Fransson P, et al. Among authors: norman d. Lancet Oncol. 2021 Feb;22(2):235-245. doi: 10.1016/S1470-2045(20)30581-7. Epub 2021 Jan 11. Lancet Oncol. 2021. PMID: 33444529 Clinical Trial.
[ROBOTICS- WHY NOW?].
Shapira J, Norman D. Shapira J, et al. Among authors: norman d. Harefuah. 2021 Nov;160(11):727-728. Harefuah. 2021. PMID: 34817138 Hebrew.
[NON-ARTHROPLASTY TREATMENT FOR KNEE OSTEOARTHRITIS].
Stahl I, Ginesin E, Hous N, Kotlyarsky P, Norman D, Peskin B. Stahl I, et al. Among authors: norman d. Harefuah. 2017 Jul;156(7):455-459. Harefuah. 2017. PMID: 28786278 Review. Hebrew.
Hypercoagulability in Kidney Transplant Recipients.
Parajuli S, Lockridge JB, Langewisch ED, Norman DJ, Kujovich JL. Parajuli S, et al. Among authors: norman dj. Transplantation. 2016 Apr;100(4):719-26. doi: 10.1097/TP.0000000000000887. Transplantation. 2016. PMID: 26413991 Review.
Optical Control of Lysophosphatidic Acid Signaling.
Morstein J, Dacheux MA, Norman DD, Shemet A, Donthamsetti PC, Citir M, Frank JA, Schultz C, Isacoff EY, Parrill AL, Tigyi GJ, Trauner D. Morstein J, et al. Among authors: norman dd. J Am Chem Soc. 2020 Jun 17;142(24):10612-10616. doi: 10.1021/jacs.0c02154. Epub 2020 Jun 5. J Am Chem Soc. 2020. PMID: 32469525 Free PMC article.
A New TALe to Tell?
White F, Norman D. White F, et al. Among authors: norman d. Cell Host Microbe. 2019 Nov 13;26(5):573-574. doi: 10.1016/j.chom.2019.10.015. Cell Host Microbe. 2019. PMID: 31726025 Free article.
Regulation of Tumor Immunity by Lysophosphatidic Acid.
Lee SC, Dacheux MA, Norman DD, Balázs L, Torres RM, Augelli-Szafran CE, Tigyi GJ. Lee SC, et al. Among authors: norman dd. Cancers (Basel). 2020 May 10;12(5):1202. doi: 10.3390/cancers12051202. Cancers (Basel). 2020. PMID: 32397679 Free PMC article. Review.
941 results